Each company is assessed on its own reporting calendar andBusinessmodel. The discussion below retains company-reported financial measures and announced plans while separating those facts from assumptions about future outcomes.
On 10 September 2026 Optiscan told the market it had reached a significant milestone in its ACL digital pathology study. The company reported an 84-case imaging milestone for its InForm device, describing the work as advancing preparation for a planned submission to the United …
On 31 August 2026 EMVision announced that recruitment into the pivotal trial of its emu bedside scanner had surpassed 200 patients. Pivotal trials are the studies regulators rely on when assessing a device, so recruitment progress is the clearest available indicator of how close …
On 21 August 2026 Nyrada announced that Xolatryp demonstrated cardioprotection in a preclinical study. Small Caps reported the underlying work as a rat model of acute myocardial ischaemia-reperfusion injury, in which the candidate showed high efficacy in limiting cardiovascular damage, positioning it as a …
Paradigm lodged four announcements on 11 September 2026. The substantive one was the drawdown of tranche 4 under its convertible note facility, accompanied by an application for quotation of securities, a notice under section 708A of the Corporations Act and a notification regarding unquoted …
On 3 September 2026 Aroa released an interim analysis from the MASTRR Registry, which it described as the largest published prospective analysis of a bioscaffold used in in-patient soft tissue reconstruction. The results appeared in theJournalAdvances in Therapy.
On 13 July 2026 Orthocell announced record FY2026 results, headlined by record quarterly revenue of A$3.8 million for the June 2026 quarter — a 20 per cent increase on the March 2026 quarter and 36 per cent higher than the prior corresponding quarter. An …
PYC Therapeutics is a clinical-stage biotechnology company developing RNA-based therapies for genetic diseases. Its platform combines designed RNA therapeutics with cell-penetrating peptides intended to deliver treatment inside target cells. The pipeline covers autosomal dominant optic atrophy, retinitis pigmentosa type 11, polycystic kidney disease and …
4DMedical develops software-based lung imaging and analysis products. Its portfolio includes CT:VQ for non-contrast ventilation and perfusion imaging, CT LungVolumeAnalysis, lung-density tools, pulmonary hypertension assessment and XV Lung Ventilation Analysis. The company uses imaging data to provide functional information intended to support clinical assessment. …
Sims is a global metal recycler and provider of circular services for digital infrastructure. Sims Metal collects and processes ferrous and non-ferrous material, while Sims Lifecycle Services manages technologyAssetsand supports data-centre infrastructure services. The group operates across multiple countries and also participates in the …